OriCell Therapeutics Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 150

Employees

  • Latest Deal Type
  • Series C

  • Latest Deal Amount
  • $110M

  • Investors
  • 16

OriCell Therapeutics General Information

Description

Manufacturer of biopharmaceuticals intended to create innovative immunotherapies for the treatment of cancer. The company offers multiple cell therapy approaches, including autologous cellular engineering, dual-target targeting constructs, armored secreting cell therapies, and in vivo engineered cell therapeutics, enabling oncology patients worldwide to access rigorously developed treatments with the potential for durable clinical benefit.

Contact Information

Website
www.oricell.com
Formerly Known As
Shanghai Yuanneng Cell Medical Technology Co., Ltd., Shanghai Yuaneng Cell Medicine Technology
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 3rd Floor, Building 1
  • Number 1227 Zhangheng Road, Pudong New Area
  • Shanghai, Shanghai 201203
  • China
+86 021
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 3rd Floor, Building 1
  • Number 1227 Zhangheng Road, Pudong New Area
  • Shanghai, Shanghai 201203
  • China
+86 021

OriCell Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

OriCell Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Later Stage VC (Series C) 16-Apr-2026 $110M Completed Generating Revenue
8. Later Stage VC (Series B1) 28-Feb-2023 Completed Generating Revenue
7. Secondary Transaction - Private 15-Feb-2023 Completed Generating Revenue
6. Secondary Transaction - Private 08-Dec-2022 Completed Generating Revenue
5. Later Stage VC (Series B) 09-Jun-2022 Completed Generating Revenue
4. Secondary Transaction - Private 24-May-2022 Completed Generating Revenue
3. Later Stage VC (Series A) 01-Dec-2020 Completed Clinical Trials - General
2. Secondary Transaction - Private 09-Dec-2020 $11.4M Completed Clinical Trials - General
1. Early Stage VC 13-Dec-2019 $11.4M $11.4M Completed Clinical Trials - General
To view OriCell Therapeutics’s complete valuation and funding history, request access »

OriCell Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Manufacturer of biopharmaceuticals intended to create innovative immunotherapies for the treatment of cancer. The compan
Drug Discovery
Shanghai, China
150 As of 2026

Shanghai, China
 

Beijing, China
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

OriCell Therapeutics Competitors (53)

One of OriCell Therapeutics’s 53 competitors is FosunKairos, a Venture Capital-Backed company based in Shanghai, China.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
FosunKairos Venture Capital-Backed Shanghai, China
Mabworks Biotech Venture Capital-Backed Beijing, China
Xenetic Biosciences Corporation Framingham, MA
CytomX Therapeutics Formerly VC-backed South San Francisco, CA
Adimab Venture Capital-Backed Lebanon, NH
You’re viewing 5 of 53 competitors. Get the full list »

OriCell Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

OriCell Therapeutics Investors (16)

Investor Name Investor Type Holding Investor Since Participating Rounds
Beijing State-owned Capital Operation and Management Government Minority
Elikon Venture Growth/Expansion Minority
Lucion Venture Capital Venture Capital Minority
Non-Government Schools Superannuation Fund Limited Partner Minority
Ruifeng Venture Capital Venture Capital Minority
You’re viewing 5 of 16 investors. Get the full list »

Ready to get started?

Request a free trial

OriCell Therapeutics FAQs

  • When was OriCell Therapeutics founded?

    OriCell Therapeutics was founded in 2015.

  • Where is OriCell Therapeutics headquartered?

    OriCell Therapeutics is headquartered in Shanghai, China.

  • What is the size of OriCell Therapeutics?

    OriCell Therapeutics has 150 total employees.

  • What industry is OriCell Therapeutics in?

    OriCell Therapeutics’s primary industry is Drug Discovery.

  • Is OriCell Therapeutics a private or public company?

    OriCell Therapeutics is a Private company.

  • What is OriCell Therapeutics’s current revenue?

    The current revenue for OriCell Therapeutics is .

  • How much funding has OriCell Therapeutics raised over time?

    OriCell Therapeutics has raised $322M.

  • Who are OriCell Therapeutics’s investors?

    Beijing State-owned Capital Operation and Management, Elikon Venture, Lucion Venture Capital, Non-Government Schools Superannuation Fund, and Ruifeng Venture Capital are 5 of 16 investors who have invested in OriCell Therapeutics.

  • Who are OriCell Therapeutics’s competitors?

    FosunKairos, Mabworks Biotech, Xenetic Biosciences, CytomX Therapeutics, and Adimab are some of the 53 competitors of OriCell Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process